Sabra Health Care price target raised to $20 from $19 at Scotiabank

Scotiabank raised the firm’s price target on Sabra Health Care (SBRA) to $20 from $19 and keeps a Sector Perform rating on the shares. Scotiabank notes recent results point to expected move-in pace remaining strong in Spring 2025 and the firm continues to see landlord pricing power since analyses show assisted living screens as more affordable than home care in the majority of REIT markets, the analyst tells investors.